Top Page | English | 简体中文 | 繁體中文 | 한국어
Tuesday, 18 June 2013, 23:45 HKT

Source: PT Bio Farma (Persero)
Bio Farma Urges OIC Countries to become Self-Reliant in Vaccine

Bandung, Indonesia, June 18, 2013 - (ACN Newswire) - The 123-year old Indonesian vaccine manufacturer Bio Farma has urged Organization of Islamic Cooperation (OIC) member countries to be self-reliant in vaccines as imports from industrialized countries are costly.

"Some Islamic countries do have their vaccine making companies but they are not yet recognized by the WHO," said Rahman Rustan, Bio Farma Corporate Secretary, in a workshop organized by Bio Farma in conjuction with the 2nd meeting of OIC vaccine- and medicine manufacturers, here.

In the workshop Indonesia offered to share experience with OIC member countries to strengthen their national regulatory authority (NRA) function in vaccine manufacuring for global markets, held on Monday, the second day of the three-day meeting that wraps up on Wednesday, 19 June 2013.

Rustan added vaccine supplies in developing countries are necessary to prevent infectious diseases, however, as there are limitations on the vaccine industry in developing countries supplies have to be imported from other countries. "We therefore encourage OIC countries to be self-reliant in vaccine," he said.

He went on to say that the vaccines that are needed are those which can be purchased at affordable prices so that they can be used in developing countries. Vaccines which are made in the developed countries are fairly expensive for imports by developing countries.

In practice, Rustan disclosed developing countries obtain vaccines at affordable prices by buying them from developing countries, including Indonesia which has Bio Farma, one of the vaccine producers in a developing country that has already received recognition and standardization of the World Health Organization (WHO).

Bio Farma itself after 123 years of existence, remains focused on research into vaccines. Even in the national immunization program in 2013 Bio Farma developed a new product called Pentabio for disease prevention of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilius Influenzae Type B.

In the workshop, Lucky S. Slamet, head of Indonesia National Agency for Food and Drug Control, also said she was to share with all OIC member countries experiences in strengthening national regulatory authority functions in vaccine manufacturing.

According to her, NRAs hold a decisive role in guaranteeing the quality of vaccine supplied to the global markets. The WHO always engages NRAs through capacity building efforts so as to ever strengthen them.

"Out of the total 57 OIC member states only five countries having their vaccine manufacturers and out of this five only one that can export its products, namely Bio Farma," Slamet emphasized.

"The WHO has declared us, the Indonesian National Agency of Food and Drug Control, to have performed an international standard control function on vaccine. With this achievement, Indonesia now has a wide opportunity - through Bio Farma - to export its products to international markets," she pointed out.

Bio Farma is Indonesia's only vaccine manufacturer whose products have been recognized by WHO since 1997 that the company can supply its products to over 120 countries.

Currently the needs for Expanded Program on Immunization (EPI) vaccines in Indonesia have been supplied solely by Bio Farma by producing and distributing over 1.7 billion doses of vaccine per year to meet the needs of EPI vaccine for national immunization program.

Bio Farma has an outstanding international reputation based on the WHO prequalification for all of its EPI vaccine products and has also implemented green industry and is environment friendly. WHO acknowledges that Bio Farma vaccine products are of high quality, efficacious, and affordable.

Bio Farma products are available through direct distribution or through various agencies such as UNICEF, PAHO. The company has obtained the Best Export Performance from the Indonesian Trade Ministry consecutively in 2010,2011, 2012 as an evidence of its consistent exceptional performance.

About PT Bio Farma (Persero)

Since its establishment in 1890, PT Bio Farma (Persero) has been active in supplying high quality vaccines and serum for people. Currently, Bio Farma is among the largest vaccines manufacturers and suppliers in the world. The need for EPI vaccines in Indonesia has been supplied solely by Bio Farma.

Bio Farma has existed for a century and proven its strength and experience world wide. The company has also grown and developed to become a vaccine and serum manufacturer of international reputation. This can be seen from its qualifications and ability to acquire WHO prequalification for all of its EPI Vaccine products. For more information, please visit

M. Rahman Rustan  
Corporate Secretary 
Bio Farma 
+62 22 2033755
+62 22 2041306
e-mail :

June 18, 2013
Source: PT Bio Farma (Persero)

Topic: Press release summary
Sectors: Biotech & Pharm
From the Asia Corporate News Network

Copyright © 2014 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 ACN Search:
PT Bio Farma (Persero)
Oct 23, 2013
Indonesia as the Hub of Excellence for Biological Products for Islamic Countries
Aug 24, 2013
Bio Farma Launches Pentavalent Vaccine, Combining Five Antigens
July 2, 2013
Bio Farma Holds Third Indonesian Vaccine Research Forum
June 18, 2013
Indonesia Warns OIC Member States of New Threats to Health
June 17, 2013
OIC Countries Mull Efforts on Vaccine Self-Reliance
June 17, 2013
Indonesia Shares Experience on Vaccine Quality Management with OIC Members
June 17, 2013
Bio Farma Urges OIC Countries to Strengthen Vaccine Cooperation
June 16, 2013
Indonesia's Agency for Food and Drug Control (BPOM) Holds Workshop on Vaccine Quality Management
June 15, 2013
Bio Farma Hosts Meeting of Islamic Vaccine-Producing Countries
Dec 6, 2012
Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant
More news >>
 News Alerts
Copyright © 2014 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 5791 1818

Connect With us: